Business Wire

Boost.ai Unveils Large Language Model Enhancements to Conversational AI Platform

11.5.2023 10:01:00 EEST | Business Wire | Press release

Share

Boost.ai, a leading conversational AI solution provider, today announced Version 12 of its platform, the first of a series of planned updates by the company to incorporate Large Language Model (LLM)-enriched features. This iteration is focused on key customer experience (CX) improvements, including content suggestion, content rewriting and accelerated generation of training data. The new update will take advantage of Generative AI to suggest messaging content to AI Trainers within the boost.ai platform, generating suggested responses and resulting in drastically reduced implementation times for new intents. With this latest release, boost.ai reinforces its commitment to researching, developing, releasing, and maintaining responsible implementations of LLM-powered, enterprise-quality conversational AI features in order to further enhance the customer experience.

ChatGPT has dominated headlines throughout 2023, yet questions about the accuracy of its underlying models, GPT-3.5 and GPT-4, persist. With an 85% accuracy rate, LLMs are a good indication of the potential of this technology in consumer-facing applications, but in their current raw state they lack the dependency for integration directly into a bank or insurance firm's systems. Boost.ai helps to resolve this issue by seamlessly integrating the predictive capabilities of LLMs with enterprise-grade control of their conversational AI platform, creating a Hybrid Natural Language Understanding (NLU) system that offers unmatched accuracy, flexibility, and cost-effectiveness. Expertly weaving together the right AI components for each task, boost.ai’s platform ensures precise and accurate answers - harnessing the benefits of LLMs, while still adhering to stringent quality assurance requirements.

“LLM technology offers great promise, but most applications just aren’t properly designed to securely and scalably support real-world businesses. With worries about accuracy or even inappropriate behavior, established institutions like banks could not risk direct access to this iteration of generative AI - until now,” said Jerry Haywood, CEO of boost.ai. “By pairing LLMs with our conversational AI, we’re able to ensure accuracy and open the door for customers in sensitive industries like financial services. We’re proud to be pioneering a way forward for businesses to harness this tech right now. It’s available for customers to use and enhance their existing solution, and to help them achieve speed to value significantly sooner whilst minimizing the risks currently dominating headlines.”

With a Hybrid NLU approach, enterprises gain the ability to combine boost.ai’s market-leading intent management, context handling, and dialogue management solutions with powerful LLM-enriched tools. Boost.ai’s existing intent engine is highly trained with guardrails in place to help guide the LLM, increasing overall accuracy and reducing the number of false positives. The end result is a chatbot that can confidently provide answers to inquiries, and a more streamlined development path that radically enhances how boost.ai customers can build scalable customer experiences for chat and voice.

“With our Hybrid NLU, we’ve been able to surpass the performance of either model on its own, providing our customers with the best of both worlds,” said Lars Ropeid Selsås, Founder of boost.ai. “Boost.ai will continue to operate at the cutting edge of AI possibility, refining our platform so that our customers are always receiving the best possible technology and service.”

On May 9th, Boost.ai co-founder, Henry Vaage Iversen and the technical team conducted a webinar highlighting the strengths of Hybrid NLU and mapping out a path for businesses to start using LLM technology to their advantage. For a recording of the full webinar, please visit: https://www.boost.ai/webinars/enhancing-cx-and-reducing-operational-costs-with-boost-ai-large-language-models

About Boost.ai

Boost.ai is a global leader in conversational AI optimized for scale. Boasting the industry's most robust intent portfolio, Boost.ai is pioneering an era of broad-scope virtual agents to deliver the most advanced and scalable technology on the market. With consistent resolution rates of 90%, Boost.ai’s market-leading virtual agent supports enterprise customers across key industries throughout the United States and Europe, including banking, insurance, telecom, retail and more. In 2021, Boost.ai was named a major player in the IDC MarketScape category, Worldwide Conversational AI Platforms for Customer Service. Key customers include Santander Bank, MSU Federal Credit Union, Aspire General Services, Tokio Marine and more. Learn more at boost.ai.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jon Burch
Boost.ai@resonancecrowd.com
+44 208 819 3170

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye